Skip to main content

IP Update: Oct 21, 2010

Premium

Title: Compositions and Methods for Inhibiting CAR Gene Expression by RNA Interference

Patent Number: 7,816,338

Filed: July 31, 2008

Lead Inventor: Tomoya Yamada, Sumitomo Chemical

The invention comprises "short interfering ribonucleic acid, compositions, and methods for inhibiting CAR gene expression simply and rapidly, which can be used for evaluating toxicity of a chemical substance," the patent's abstract states.


Title: siRNA Targeting Proto-Oncogene MET

Patent Number: 7,816,512

Filed: Nov. 2, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET."


Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression

Patent Number: 7,816,581

Filed: Oct. 10, 2006

Lead Inventor: Larry Gilbertson, Monsanto Technology

The invention comprises "molecular constructs and methods for use thereof, including constructs [featuring] heterologous miRNA recognition sites; constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence; constructs containing engineered miRNA or miRNA precursors; and constructs for suppression of production of mature microRNA in a cell.

The invention also comprises "transgenic plant cells, plants, and seeds containing such constructs, and methods for their use," the abstract adds. "The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy."


Title: Use of Short Oligonucleotides for Reagent Redundancy Experiments in RNA Functional Analysis

Application Number: 20100261175

Filed: June 12, 2008 PCT Filed: June 12, 2008

Lead Inventor: Soeren Vestergaard Rasmussen, Exiqon

The invention, the patent application's abstract states, "relates to functional analysis of miRNAs or other short non-coding RNAs involving the use of two or more sequence-distinct miRNAs antagonizing oligomeric compounds, which enables the reagent redundancy experiments to reduce the risk of reporting false positive effects of miRNA/ncRNA antagonists."


Title: Method for the Chemical Synthesis of Oligonucleotides

Application Number: 20100261890

Filed: June 10, 2010

Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)

The invention "features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof," the patent application's abstract states.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.